ANXA2 and glioblastoma: Focusing on the GBM dataset, ANXA2 expression was significantly associated with poorer survival in the CGGA GBM dataset (ANXA2 high, median survival = 14.4 months; ANXA2 low, median survival = 19.8 months; P = 0.01), though the difference was not statistically significant in the TCGA GBM dataset (ANXA2 high, median survival = 12.6 months; ANXA2 low, median survival = 14.9 months; P = 0.097) (Additional file 12: Supplementary Fig. S10A).